氯法拉滨-氟达拉滨-白消安用于儿童白血病造血细胞移植:一种有效、低毒性、不含全身照射的预处理方案
该前瞻性研究纳入2011至2019年接受首次异基因造血细胞移植的155例儿童白血病患者,均接受氯法拉滨-氟达拉滨-白消安预处理。2年无事件生存率在急性淋巴细胞白血病为72.0%±6.0,在急性髓系白血病为62.4%±6.0;治疗相关死亡率为11.0%±2.6。作者认为该方案毒性有限且无事件生存令人鼓舞,但需随机前瞻性研究。
要点
- 氯法拉滨-氟达拉滨-白消安预处理后2年无事件生存率:急性淋巴细胞白血病72.0%±6.0,急性髓系白血病62.4%±6.0。
- 全队列治疗相关死亡率为11.0%±2.6,6个月时3至4级急性移植物抗宿主病发生率为12.3%±2.7。
- 移植前微小残留病阳性与急性淋巴细胞白血病和急性髓系白血病更高的累积复发率相关。
核心结论
- 氯法拉滨-氟达拉滨-白消安方案毒性有限且无事件生存令人鼓舞,可能是较传统预处理方案毒性更低的替代选择,但需随机前瞻性研究。
研究设计与样本
- 前瞻性研究,纳入2011至2019年接受首次异基因造血细胞移植的155例儿童患者,均接受氯法拉滨-氟达拉滨-白消安预处理。
- 纳入患者包括60例急性淋巴细胞白血病、69例急性髓系白血病和26例其他恶性肿瘤(主要为MDS-EB)。
- 中位年龄为9.7岁(范围0.5至18.6岁)。
- 主要终点为无事件生存率,次要终点包括总生存率、移植物抗宿主病-无复发生存率、治疗相关死亡率、累积复发率、急性和慢性移植物抗宿主病及静脉闭塞性疾病。
- 数据分析采用Cox比例风险模型和Fine和Gray竞争风险模型。
主要发现
- 估计2年无事件生存率在急性淋巴细胞白血病患者为72.0%±6.0,在急性髓系白血病患者为62.4%±6.0。
- 全队列治疗相关死亡率为11.0%±2.6。
- 6个月时3至4级急性移植物抗宿主病发生率为12.3%±2.7。
- 2年时广泛型慢性移植物抗宿主病发生率为6.4%±2.1。
- 移植前微小残留病阳性与急性淋巴细胞白血病和急性髓系白血病更高的累积复发率相关。
临床怎么用
- 作者认为氯法拉滨-氟达拉滨-白消安是较传统预处理方案毒性更低的潜在替代选择,但需随机前瞻性研究验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity. All patients receiving their first HCT, from 2011-2019, were included and received CloFluBu. The primary endpoint was event-free survival (EFS). Secondary endpoints were overall survival (OS), graft-versus-host disease (GvHD)-relapse-free survival (GRFS), treatment-related mortality (TRM), cumulative incidence of relapse (CIR), acute and chronic GvHD (aGvHD and cGvHD), and veno-occlusive disease (VOD). Cox proportional hazard and Fine and Gray competing-risk models were used for data analysis. One hundred fifty-five children were included: 60 acute lymphoid leukemia (ALL), 69 acute myeloid leukemia (AML), and 26 other malignancies (mostly MDS-EB). The median age was 9.7 (0.5 to 18.6) years. Estimated 2-year EFS was 72.0% ± 6.0 in ALL patients, and 62.4% ± 6.0 in AML patients. TRM in the whole cohort was 11.0% ± 2.6, incidence of aGvHD 3 to 4 at 6 months was 12.3% ± 2.7, extensive cGvHD at 2 years was 6.4% ± 2.1. Minimal residual disease-positivity prior to HCT was associated with higher CIR, both in ALL and AML. CloFluBu showed limited toxicity and encouraging EFS. CloFluBu is a potentially less toxic alternative to conventional conditioning regimens. Randomized prospective studies are needed.
引用
- Versluijs AB, de Koning CCH, Lankester AC, et al. Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood Adv. 2022. PMID: 34781362. doi:10.1182/bloodadvances.2021005224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。